Report : North America Coagulation Analyzers Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Clinical Laboratory Analyzers and Point-of-Care Testing Analyzers), Test (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Activated Partial Thromboplastin Time Testing, D-Dimer Testing, Platelet Function Tests, Anti-Factor XA Tests, Heparin and Protamine Dose Response Tests for ACT, and Others), Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, and Other Technologies), and End Users (Hospitals, Clinical Laboratories, Point-of-Care Testing, and Others)
At 5.8% CAGR, the North America Coagulation Analyzers Market is speculated to be worth US$ 2,529.13 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the North America coagulation analyzers market was valued at US$ 1,802.76 million in 2022 and is expected to reach US$ 2,529.13 million by 2028, registering a CAGR of 5.8% from 2022 to 2028. Increasing prevalence of blood disorders and rising cardiovascular diseases are the critical factors attributed to the North America coagulation analyzers market expansion.
A coagulation analyzer is a device that measures and evaluates the speed of clot formation or clot coagulation. It provides a fast, simple way to measure blood platelet levels and thrombolin and thromboplastin levels accurately. According to the National Organizations of Rare Disorders, hemophilia A is a common X-linked recessive disorder and the second most common inherited clotting factor deficiency after von Willebrand disease. In the US, approximately 1 in 5,000 newborn males suffer from hemophilia A. According to the National Library of Medicine (NLM), in 2020, approximately 30,000-33,000 males were affected with hemophilia in the US. According to the US Department of Health & Human Services, in 2020, ~100,000 Americans had sickle cell disease (SCD), the most commonly inherited blood disorder. Furthermore, by 2050, the number of people suffering from SCD is expected to grow by ~30%. As per the National Library of Medicine, in 2022, ~1% of all individuals (unselected population) are suffering from von Willebrand disease, i.e., 125 per 1 million. According to National Organization for Rare Disorders, in 2022, in the US immune thrombocytopenia (ITP), an autoimmune bleeding disorder, affects approximately 66 adults per 1 million each year. Moreover, in the US, the incidence of ITP in adults is ~3.3 per 100,000/year, while the prevalence is 9.5 per 100,000. Thus, the increasing prevalence of blood disorders is driving the North America coagulation analyzers market growth.
On the contrary, high costs and stringent regulations associated with coagulation analyzers hampers the North America coagulation analyzers market.
Based on product, the North America coagulation analyzers market is segmented into clinical laboratory analyzers and point-of-care testing analyzers. The clinical laboratory segment held 66.7% share of North America coagulation analyzers market in 2022, amassing US$ 1,202.50 million. It is projected to garner US$ 1,625.64 million by 2028 to expand at 5.2% CAGR during 2022–2028.
Based on test, the North America coagulation analyzers market is segmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimer testing, platelet function tests, anti-factor xa tests, heparin and protamine dose response tests for act, and others. The prothrombin time testing segment held 53.1% share of North America coagulation analyzers market in 2022, amassing US$ 957.08 million. It is projected to garner US$ 1,342.93 million by 2028 to expand at 5.8% CAGR during 2022–2028.
Based on technology, the North America coagulation analyzers market is segmented into optical technology, mechanical technology, electrochemical technology, and other technologies. The optical technology segment held 59.3% share of North America coagulation analyzers market in 2022, amassing US$ 1,069.80 million. It is projected to garner US$ 1,514.33 million by 2028 to expand at 6.0% CAGR during 2022–2028.
Based on end users, the North America coagulation analyzers market is segmented into hospitals, clinical laboratories, point-of-care testing, and others. The clinical laboratories segment held 60.2% share of North America coagulation analyzers market in 2022, amassing US$ 1,085.95 million. It is projected to garner US$ 1,540.29 million by 2028 to expand at 6.0% CAGR during 2022–2028.
Based on country, the North America coagulation analyzers market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 85.5% share of North America coagulation analyzers market in 2022. It was assessed at US$ 1,542.03 million in 2022 and is likely to hit US$ 2,164.01 million by 2028, exhibiting a CAGR of 5.8% during the forecast period.
Key players dominating the North America coagulation analyzers market are Abbott Laboratories; Danaher Corp; F. Hoffmann-La Roche Ltd; Horiba Ltd.; Nihon Kohden Corp; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Sysmex Corporation; and Thermo Fisher Scientific Inc, among others.
- In March 2022; Mindray Launched the BC-700 Series, a Compact, Integrated CBC & ESR Hematology Analyzer for Small-to-mid Sized Labs. It incorporates both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com